ReviewDeutsches Arzteblatt international2017
Treatment Options in Hepatitis C.
Review in Deutsches Arzteblatt international, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 37 citations in OpenAlex.
- ReLink strategy in diagnosed-but-untreated hepatitis C-positive patients in Germany: report from a single center.Zeitschrift fur Gastroenterologie · 2024Article
- Advancements in Antiviral Drug Development: Comprehensive Insights into Design Strategies and Mechanisms Targeting Key Viral Proteins.Journal of microbiology and biotechnology · 2024Review
- Outcomes of liver resection in hepatitis C virus-related intrahepatic cholangiocarcinoma: A systematic review and meta-analysis.World journal of virology · 2024Article
- Current Therapy of Chronic Viral Hepatitis B, C and D.Journal of personalized medicine · 2023Review
- Challenges Facing Viral Hepatitis C Elimination in Lebanon.Pathogens (Basel, Switzerland) · 2023Review
- [Treatment of parenterally transmittable viral hepatitis].Der Internist · 2022Review
- [Treatment of hepatitis C infections in the era of direct-acting antivirals (DAAs)].Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz · 2022Review
- Hepatitis C in healthcare personnel: follow-up analysis of treatments with direct-acting antiviral agents.Journal of occupational medicine and toxicology (London, England) · 2021Article
- Safety, Tolerability and Pharmacokinetics of Yimitasvir Phosphate Capsule, a Novel Oral Hepatitis C Virus NS5A Inhibitor, in Healthy Chinese Volunteers.Clinical drug investigation · 2019Article
- Cerebral patterns of neuropsychological disturbances in hepatitis C patients.Journal of neurovirology · 2019Article
- Effectiveness and Safety of Direct-Acting Antiviral Combination Therapies for Treatment of Hepatitis C Virus in Elderly Patients: Results from the German Hepatitis C Registry.Drugs & aging · 2018Article
- [Chronic hepatitis C : Standard treatment and remaining challenges].Der Internist · 2018Review
- Hepatitis C in healthcare personnel: secondary data analysis of therapies with direct-acting antiviral agents.Journal of occupational medicine and toxicology (London, England) · 2018Article
- Hepatitis C is now curable, but what happens with cirrhosis and portal hypertension afterwards?Clinical and experimental hepatology · 2017Review
- Drug Treatment for Chronic Hepatitis C Infection and Cancer Risk.Deutsches Arzteblatt international · 2017Article
- The Treatment of Hepatitis C- An Introduction to the Use of New Medicines.Deutsches Arzteblatt international · 2017Article
- Impact of newer direct-acting antiviral drugs based on quality-adjusted life years: A prospective pharmacoeconomic study in hepatitis C patients.Perspectives in clinical researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAmong patients with chronic hepatitis C, 20-30% develop hepatic cirrhosis and its complications within 30 years. The antiviral treatment of hepatitis C, previously interferon-based, has recently become inter - feron-free, with resulting improvements in sustained virological response rates, safety, and tolerability and a shorter duration of treatment.
methodsThis review is based on relevant publications retrieved by a selective literature search, and particularly on studies and reviews concerning the course and treatment of hepatitis C.
resultsThe available drugs for interferon-free antiviral treatment of hepatitis C include inhibitors of the RNAdependent RNA polymerase, NS3/4A protease, and NS5A protein of the hepatitis C virus (HCV), and ribavirin. Typically, two specific inhibitors are given in combination; the usual duration of treatment is 12 weeks.The antiviral drugs differ in their genotypic antiviral effectiveness and resistance barriers. The appropriate drug(s) should be chosen in consideration of the patient's hepatic and renal function and potential drug interactions. These drugs are safe and well-tolerated and result in sustained virological response rates between 90% and 100%.
conclusionAll patients with hepatitis C, whatever their disease stage, can derive a sustained eradication of HCV from a combination of drugs with direct antiviral activity. Viral eradication is associated with a better quality of life and with lower morbidity and mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.